Overview

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Status:
Unknown status

Trial end date:
2018-12-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open-label control trial of two arms conducted at 10 centres in China.The aim was to investigate whether sequential combination therapy with Thymosin alpha 1 and entecavir is superior to continuous ETV monotherapy in HBeAg-positive chronic hepatitis B patients with previous long-term entecavir therapy (≥ 2 years), and to select the optimal patients who may benefit from sequential combination therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Wen-hong Zhang

Treatments:

Entecavir
Thymalfasin